PDS Biotech Reports 36-Month Overall Survival Rate Of 84.4% In Phase 2 Trial For Locally Advanced Cervical Cancer Patients Treated With Versamune HPV And Chemoradiation; 100% Survival And Progression-Free Rates In Fully Treated Patients
Portfolio Pulse from Benzinga Newsdesk
PDS Biotech announced a 36-month overall survival rate of 84.4% in a Phase 2 trial for locally advanced cervical cancer patients treated with Versamune HPV and chemoradiation. Fully treated patients showed 100% survival and progression-free rates.
October 02, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech's Phase 2 trial results for Versamune HPV show an 84.4% overall survival rate and 100% survival in fully treated patients, indicating strong efficacy in treating locally advanced cervical cancer.
The positive trial results for Versamune HPV suggest strong efficacy, which is likely to boost investor confidence and positively impact PDS Biotech's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100